Pneumocystis carinii Pneumonia: A Clinical Review

Am Fam Physician. 1999 Oct 15;60(6):1699-1708.

  See related patient information handout on PCP, adapted by the authors of this article from information offered by the CDC.

Pneumocystis carinii pneumonia (PCP) is an opportunistic infection that occurs in immunosuppressed populations, primarily patients with advanced human immunodeficiency virus infection. The classic presentation of nonproductive cough, shortness of breath, fever, bilateral interstitial infiltrates and hypoxemia does not always appear. Diagnostic methods of choice include sputum induction and bronchoalveolar lavage. The drug of choice for treatment and prophylaxis is trimethoprim-sulfamethoxazole, but alternatives are often needed because of adverse effects or, less commonly, treatment failure. Adjunctive corticosteroid therapy improves survival in moderate to severe cases. Complications such as pneumothorax and respiratory failure portend poorer survival. Prophylaxis dramatically lowers the risk of disease in susceptible populations. Although PCP has declined in incidence in the developed world as a result of prophylaxis and effective antiretroviral therapy, its diagnosis and treatment remain challenging.

Before the epidemic of acquired immunodeficiency syndrome (AIDS) in the early 1980s, Pneumocystis carinii pneumonia (PCP) was a rare infection that occurred in immunosuppressed patients with protein malnutrition or acute lymphocytic leukemia, or in patients receiving corticosteroid therapy. This opportunistic infection is now most commonly associated with advanced human immunodeficiency virus (HIV) infection.

The appearance of PCP in previously healthy gay men was one of the initial signs of the emergence of AIDS.1 Before the widespread use of prophylaxis, PCP was the AIDS-defining illness in 60 percent of cases and eventually affected 80 percent of patients with AIDS.2,3 Earlier diagnosis of HIV, antiretroviral therapy and effective prophylaxis have all contributed to a 75 percent decline in cases,4 although PCP remains the most common AIDS-defining illness. Intravenous drug users, noncompliant patients and persons whose HIV serostatus is unknown are at particularly high risk. Intolerance of antipneumocystis agents is common, making management challenging.

Controversy exists over whether PCP represents reactivation of infection acquired early in life or whether repeated exposure and reinfection cause the disease. Experiments in immunosuppressed animals and reports of case clusters support the latter theory.5 The organism is acquired by inhalation and adheres to type I alveolar cells. Proliferation produces a foamy, eosinophilic exudate that fills the alveolar spaces, leading to decreased oxygenation, a thickened interstitium and, eventually, fibrosis.6

Risk Factors and Clinical Presentation

Defective T-cell immunity is the primary risk factor for PCP. Associated clinical signs are well defined in HIV infection and reflect the degree of CD4+ cell depletion7,8  (Table 1).

TABLE 1

Risk Factors for PCP in HIV-Positive Patients

CD4+ T-lymphocyte cell count < 200 per mm3 (200 × 106 per L)*

Unexplained fever of > 37.7°C (100°F) for > two weeks*

History of oropharyngeal candidiasis*

Previous episode of PCP*

Other AIDS-defining illness


PCP = Pneumocystis carinii pneumonia; HIV = human immunodeficiency syndrome; AIDS = acquired immunodeficiency syndrome.

*—Risk defined in 1997 U.S. Public Health Service guidelines.

TABLE 1   Risk Factors for PCP in HIV-Positive Patients

View Table

TABLE 1

Risk Factors for PCP in HIV-Positive Patients

CD4+ T-lymphocyte cell count < 200 per mm3 (200 × 106 per L)*

Unexplained fever of > 37.7°C (100°F) for > two weeks*

History of oropharyngeal candidiasis*

Previous episode of PCP*

Other AIDS-defining illness


PCP = Pneumocystis carinii pneumonia; HIV = human immunodeficiency syndrome; AIDS = acquired immunodeficiency syndrome.

*—Risk defined in 1997 U.S. Public Health Service guidelines.

The signs and symptoms of PCP can be subtle. The diagnosis requires a heightened index of suspicion because risk factors for HIV may be denied, remote or unknown. The classic triad of fever, exertional dyspnea and nonproductive cough is noted in just over 50 percent of cases. However, almost all patients with PCP have at least two of the following: fever, cough, dyspnea, lactate dehydrogenase (LDH) level of more than 460 U per L or an arterial partial pressure of oxygen (PaO2) of less than 75 mm Hg. Symptoms typically progress slowly, over weeks to months; careful questioning may reveal longstanding, progressive exertional dyspnea (in contrast to HIV-seronegative patients, who typically have a more rapid onset9).

Physical findings are also nonspecific. Auscultation may reveal fine dry rales or may be unremarkable. In 2 to 6 percent of cases, PCP may present with a spontaneous pneumothorax.10 Extrapulmonary pneumocystosis occurs rarely, involving organs such as the heart, skin, spleen, thyroid or eyes.

Elevated serum LDH is not specific enough to distinguish PCP from other types of pneumonia, but the degree of elevation may provide evidence of the severity of the illness. A decrease in oxygen saturation as measured by pulse oximetry during exercise suggests PCP, especially in the patient who has minimal symptoms, does not appear acutely ill and has an unimpressive chest radiograph. When blood gas analysis reveals hypoxemia or a widened alveolar-to-arterial oxygen difference ([A-a]Do2), the prognostic and therapeutic implications are unfavorable (Table 2).

TABLE 2

Use of [A-a]Do2 to Determine PCP Severity

A. Calculation of alveolar-arterial oxygen difference

  • Specimens for arterial blood gas analysis are drawn while patient is breathing room air (Flo2 = 21%).

  • The following formula is used to determine alveolar-to-arterial oxygen difference:

    [A-a]DO2 = 150 - 1.2(Paco2) - Pao2

B. Grading severity of PCP by oxygenation

Severity

[A-a]Do2 (mm Hg)

Pao2 (mm Hg)


Mild

< 35

> 70

Moderate

35 to 45

> 70

Severe

> 45

> 50


[A-a]Do2 = alveolar-to-arterial oxygen difference; PCP = Pneumocystis carinii pneumonia; Flo2 = fraction of inspired oxygen; Paco2 = arterial partial pressure of carbon dioxide; Pao2 = arterial partial pressure of oxygen.

TABLE 2   Use of [A-a]Do2 to Determine PCP Severity

View Table

TABLE 2

Use of [A-a]Do2 to Determine PCP Severity

A. Calculation of alveolar-arterial oxygen difference

  • Specimens for arterial blood gas analysis are drawn while patient is breathing room air (Flo2 = 21%).

  • The following formula is used to determine alveolar-to-arterial oxygen difference:

    [A-a]DO2 = 150 - 1.2(Paco2) - Pao2

B. Grading severity of PCP by oxygenation

Severity

[A-a]Do2 (mm Hg)

Pao2 (mm Hg)


Mild

< 35

> 70

Moderate

35 to 45

> 70

Severe

> 45

> 50


[A-a]Do2 = alveolar-to-arterial oxygen difference; PCP = Pneumocystis carinii pneumonia; Flo2 = fraction of inspired oxygen; Paco2 = arterial partial pressure of carbon dioxide; Pao2 = arterial partial pressure of oxygen.

The chest film typically shows diffuse interstitial or perihilar infiltrates but can be normal in at least one third of cases11 (Figures 1a and 1b). Pneumatoceles increase the risk of pneumothorax.10 Less commonly, lobar infiltrates, effusions or cavitary lesions mimic other pulmonary processes. Many other diseases may have a similar presentation, including mycobacterial, fungal, viral or bacterial pneumonias, heart failure, Kaposi's sarcoma and pulmonary emboli.

FIGURE 1A.

Bilateral interstitial infiltrates in an HIV-infected patient with Pneumocystis carinii pneumonia (PCP).

View Large


FIGURE 1A.

Bilateral interstitial infiltrates in an HIV-infected patient with Pneumocystis carinii pneumonia (PCP).


FIGURE 1A.

Bilateral interstitial infiltrates in an HIV-infected patient with Pneumocystis carinii pneumonia (PCP).

FIGURE 1B.

Ventilator-associated right-sided pneumothorax in the same patient.

View Large


FIGURE 1B.

Ventilator-associated right-sided pneumothorax in the same patient.


FIGURE 1B.

Ventilator-associated right-sided pneumothorax in the same patient.

Diagnosis

P. carinii cannot be routinely cultured and is identified by stains demonstrating the cyst wall or the trophozoite (Figure 2). Before the emergence of AIDS, PCP was diagnosed by open lung biopsy. Less invasive procedures—sputum induction and bronchoalveolar lavage—are now the methods of choice12  (Table 3).

FIGURE 2.

Methenamine silver stain of a bronchoalveolar lavage specimen showing a cluster of P. carinii cysts.

View Large


FIGURE 2.

Methenamine silver stain of a bronchoalveolar lavage specimen showing a cluster of P. carinii cysts.


FIGURE 2.

Methenamine silver stain of a bronchoalveolar lavage specimen showing a cluster of P. carinii cysts.

TABLE 3

Comparison of Induced Sputum and Bronchoalveolar Lavage

Induced sputum Bronchoalveolar lavage

Nebulized saline inhaled by patient to promote deep cough

Saline instilled through bronchoscope wedged in airway and fluid withdrawn

Inexpensive; noninvasive

More expensive, more invasive, risk of Periprocedural sedation, requires skilled personnel

Specimen processing more complex, may delay diagnosis of another pathogen

Larger samples can be sent for staining and can be used to diagnose other infections (bacterial, fungal, viral and mycobacterial cultures)

Less sensitive

> 95 percent sensitive

TABLE 3   Comparison of Induced Sputum and Bronchoalveolar Lavage

View Table

TABLE 3

Comparison of Induced Sputum and Bronchoalveolar Lavage

Induced sputum Bronchoalveolar lavage

Nebulized saline inhaled by patient to promote deep cough

Saline instilled through bronchoscope wedged in airway and fluid withdrawn

Inexpensive; noninvasive

More expensive, more invasive, risk of Periprocedural sedation, requires skilled personnel

Specimen processing more complex, may delay diagnosis of another pathogen

Larger samples can be sent for staining and can be used to diagnose other infections (bacterial, fungal, viral and mycobacterial cultures)

Less sensitive

> 95 percent sensitive

In a center with experienced staff, induced-sputum examination rapidly diagnosed PCP in 80 percent of confirmed cases,13 although rates vary greatly, with sensitivities ranging from 30 to 90 percent.12 Bronchoscopy with bronchoalveolar lavage is useful because it samples the alveolar contents with a sensitivity that exceeds 95 percent. Lavage of two or more segments, particularly in the upper lobes, increases the yield.14 Because transbronchial biopsy carries a 10 percent risk of pneumothorax, it is usually reserved for use in situations in which bronchoalveolar lavage fails to reveal PCP in a patient with a compatible presentation, or when another process, such as tuberculosis, fungal infection or neoplasm, is suspected.13 These diagnostic methods may be less satisfactory in HIV-seronegative patients, because these patients have fewer organisms and a more pronounced inflammatory response.15

It is crucial to make a diagnosis as quickly as possible so that targeted therapy can be initiated. Some experts advocate employing empiric therapy when the clinical presentation is compatible with PCP. Because of the many variables in presentation and radiographic findings, empiric therapy involves the risk of unnecessary (and potentially toxic) treatment and the possibility of overlooking another important diagnosis, such as tuberculosis. In a large retrospective review,16 it was found that patients treated empirically had a significantly higher mortality rate than those who underwent diagnostic bronchoscopy. In a series of 894 AIDS patients with fever and respiratory symptoms evaluated by bronchoalveolar lavage, PCP was found in only one half—and of these, 20 percent had coexistent infections.17 It is certainly acceptable to start PCP treatment while awaiting definitive diagnostic testing, without compromising its accuracy.

Management of PCP

Available therapies have many adverse effects, and treatment is more often limited by toxicity than by lack of response. Patients with AIDS require three weeks of treatment for PCP, compared with two weeks in other populations.9  Hospitalized patients should receive intravenous therapy until they improve enough to reliably absorb oral medication; those with mild disease can be treated orally from the outset. Table 4 presents suggested treatment choices based on the authors' interpretation of clinical trial results, the severity of the episode and the potential adverse effects. All patients should be monitored closely for signs of toxicity and clinical deterioration.

TABLE 4

Suggested Hierarchy of Treatment Choices for PCP

Mild to moderate PCP (oral regimens)

First choice

Trimethoprim-sulfamethoxazole (Bactrim, Septra)

Second choice

Trimethoprim (Proloprim) and dapsone

or

Clindamycin (Cleocin) and primaquine

Third choice

Atovaquone (Mepron)

Moderate to severe PCP (IV regimens)

First choice

Trimethoprim-sulfamethoxazole

Second choice

Trimetrexate/leucovorin and oral dapsone

or

Clindamycin (Cleocin phosphate) and oral primaquine

Third choice

Pentamidine


note: Alternative regimens are considered to be equivalent or near-equivalent choices.

PCP = Pneumocystis carinii pneumonia; IV = intravenously.

TABLE 4   Suggested Hierarchy of Treatment Choices for PCP

View Table

TABLE 4

Suggested Hierarchy of Treatment Choices for PCP

Mild to moderate PCP (oral regimens)

First choice

Trimethoprim-sulfamethoxazole (Bactrim, Septra)

Second choice

Trimethoprim (Proloprim) and dapsone

or

Clindamycin (Cleocin) and primaquine

Third choice

Atovaquone (Mepron)

Moderate to severe PCP (IV regimens)

First choice

Trimethoprim-sulfamethoxazole

Second choice

Trimetrexate/leucovorin and oral dapsone

or

Clindamycin (Cleocin phosphate) and oral primaquine

Third choice

Pentamidine


note: Alternative regimens are considered to be equivalent or near-equivalent choices.

PCP = Pneumocystis carinii pneumonia; IV = intravenously.

The mainstay of treatment is trimethoprim-sulfamethoxazole (Bactrim, Septra), given intravenously or orally (Table 5). Trimethoprim-sulfamethoxazole sequentially inhibits two enzymes in folate metabolism essential for DNA synthesis: dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS).18 Treatment failure occurs in 9 to 20 percent of cases, depending on severity.19,20 However, adverse effects are reported in more than one half of cases, and treatment-limiting toxicities may occur in up to one third.19 Common problems include nausea and vomiting, maculopapular rash, bone marrow suppression, hepatitis and drug fever20  (Table 4). Management of adverse effects by means of antiemetics, antihistamines or antipyretics may enable completion of a course of therapy.

TABLE 5

Drugs for Treatment of PCP

Regimen Dosage Common adverse effects Cost*

Trimethoprim-sulfamethoxazole (Bactrim, Septra)

5 mg per kg of trimethoprim component every 8 hours, IV or orally (for most patients, oral dosage is 2 double-strength tablets three times daily)

Maculopapular rash, fever, bone marrow suppression, hepatitis, nausea, vomiting, hyperkalemia

$137, generic†

8, brand‡

Pentamidine

4 mg per kg IV once daily, infused over 60 minutes

Hypo- or hyperglycemia and subsequent diabetes mellitus, arrhythmias, QT interval prolongation, leukopenia, pancreatitis, bone marrow suppression, hepatitis, fever

99, brand

Trimetrexate (Neutrexin) and leucovorin

Trimetrexate§: for patients < 50 kg—1.5 mg per kg per day IV; for patients 50 to 80 kg—1.2 mg per kg per day IV; for patients > 80 kg—1.0 mg per kg per day IV

Neutropenia, thrombocytopenia

264, brand

Leucovorin§: for patients < 50 kg—0.8 mg per kg IV or orally every 6 hours; for patients ≥50 kg—0.5 mg per kg IV or orally every 6 hours (round off to next highest dosage when using leucovorin orally); continue leucovorin for 72 hours after last trimetrexate dose.

20 to 70, generic† 98 to 163, generic‡

May add dapsone, 100 mg per day orally.

0.20 to 0.30, generic

Trimethoprim (Proloprim) and dapsone

Trimethoprim, 5 mg per kg orally every 8 hours and dapsone, 100 mg orally once daily

Nausea, vomiting, fever, rash, bone marrow suppression, hepatitis, hemolysis, methemoglobinemia

7, brand (2 to 3, generic)

0.20 to 0.30, generic

Clindamycin (Cleocin) and primaquine

Clindamycin, 600 to 900 mg IV or 300 to 400 mg orally every 6 to 8 hours Primaquine base, 15 to 30 mg orally once daily∥

Rash, anemia, neutropenia, methemoglobinemia, hemolysis

42, brand (2 to 3, generic)† 10, brand‡ (3 to 7, generic) 0.75, brand

Atovaquone (Mepron)

750 mg of suspension orally three times daily with fatty foods (do not use in patients with diarrhea or malabsorption)

Nausea, vomiting, rash

42, brand


PCP = Pneumocystis carinii pneumonia; IV = intravenously.

*—Estimated cost to the pharmacist based on average wholesale prices (rounded to the nearest dollar for prices above $1) for one day of treatment based on a patient weighing 70 kg (154 lb) in Red book. Montvale, N.J.: Medical Economics Data, 1999. Cost to the patient may be greater, depending on prescription filling fee.

†—IV.

‡—Oral.

§—Updated basis for dosing.

∥—One tablet (26.3 mg) is the equivalent of 15 mg base.

TABLE 5   Drugs for Treatment of PCP

View Table

TABLE 5

Drugs for Treatment of PCP

Regimen Dosage Common adverse effects Cost*

Trimethoprim-sulfamethoxazole (Bactrim, Septra)

5 mg per kg of trimethoprim component every 8 hours, IV or orally (for most patients, oral dosage is 2 double-strength tablets three times daily)

Maculopapular rash, fever, bone marrow suppression, hepatitis, nausea, vomiting, hyperkalemia

$137, generic†

8, brand‡

Pentamidine

4 mg per kg IV once daily, infused over 60 minutes

Hypo- or hyperglycemia and subsequent diabetes mellitus, arrhythmias, QT interval prolongation, leukopenia, pancreatitis, bone marrow suppression, hepatitis, fever

99, brand

Trimetrexate (Neutrexin) and leucovorin

Trimetrexate§: for patients < 50 kg—1.5 mg per kg per day IV; for patients 50 to 80 kg—1.2 mg per kg per day IV; for patients > 80 kg—1.0 mg per kg per day IV

Neutropenia, thrombocytopenia

264, brand

Leucovorin§: for patients < 50 kg—0.8 mg per kg IV or orally every 6 hours; for patients ≥50 kg—0.5 mg per kg IV or orally every 6 hours (round off to next highest dosage when using leucovorin orally); continue leucovorin for 72 hours after last trimetrexate dose.

20 to 70, generic† 98 to 163, generic‡

May add dapsone, 100 mg per day orally.

0.20 to 0.30, generic

Trimethoprim (Proloprim) and dapsone

Trimethoprim, 5 mg per kg orally every 8 hours and dapsone, 100 mg orally once daily

Nausea, vomiting, fever, rash, bone marrow suppression, hepatitis, hemolysis, methemoglobinemia

7, brand (2 to 3, generic)

0.20 to 0.30, generic

Clindamycin (Cleocin) and primaquine

Clindamycin, 600 to 900 mg IV or 300 to 400 mg orally every 6 to 8 hours Primaquine base, 15 to 30 mg orally once daily∥

Rash, anemia, neutropenia, methemoglobinemia, hemolysis

42, brand (2 to 3, generic)† 10, brand‡ (3 to 7, generic) 0.75, brand

Atovaquone (Mepron)

750 mg of suspension orally three times daily with fatty foods (do not use in patients with diarrhea or malabsorption)

Nausea, vomiting, rash

42, brand


PCP = Pneumocystis carinii pneumonia; IV = intravenously.

*—Estimated cost to the pharmacist based on average wholesale prices (rounded to the nearest dollar for prices above $1) for one day of treatment based on a patient weighing 70 kg (154 lb) in Red book. Montvale, N.J.: Medical Economics Data, 1999. Cost to the patient may be greater, depending on prescription filling fee.

†—IV.

‡—Oral.

§—Updated basis for dosing.

∥—One tablet (26.3 mg) is the equivalent of 15 mg base.

Intravenous pentamidine may be somewhat less effective than trimethoprim-sulfamethoxazole for the treatment of moderate to severe PCP.20 It is usually reserved for use in patients who do not respond to, or cannot tolerate, trimethoprim-sulfamethoxazole. Serious adverse effects include nephrotoxicity, hyperglycemia and hypoglycemia, pancreatitis, arrhythmias (including torsade de pointes) and the subsequent development of frank diabetes.18 It is important to monitor blood glucose and creatinine levels and to watch for QT prolongation, especially during the last two weeks of therapy.

Trimetrexate (Neutrexin) is a significantly more potent inhibitor of DHFR than trimethoprim (Proloprim),18 so potent that hematopoietic cells must be protected through the coadministration of leucovorin. Although trimetrexate is significantly less toxic than trimethoprim-sulfamethoxazole, it is also less effective.21 Because it is administered once daily, trimetrexate can be used in outpatients even though it is given intravenously. To mimic the sequential enzyme blockade provided by trimethoprim-sulfamethoxazole, dapsone (100 mg orally) can be added to the regimen.

Besides trimethoprim-sulfamethoxazole, several alternative treatment regimens can be used in patients with mild or moderate PCP. Therapy with dapsone and trimethoprim duplicates the sequential enzyme blockade of trimethoprim-sulfamethoxazole.19 Although dapsone can trigger hemolytic anemia in patients with absolute (homozygous) glucose-6-phosphate dehydrogenase (G6PD) deficiency, black patients typically have relative (heterozygous) G6PD deficiency and tolerate dapsone therapy without significant hemolysis.

Clindamycin (Cleocin) plus primaquine is another useful oral combination. Anemia is a common complication of this therapy, but it is rarely due to hemolysis. Rash, which typically appears in the second week of use, may be severe and is more common than rash related to trimethoprim-sulfamethoxazole.19

When trimethoprim-sulfamethoxazole, dapsone-trimethoprim and clindamycin-primaquine were compared in patients with mild-to-moderate PCP, no significant differences were found in terms of either therapeutic failure or treatment-limiting toxicity; 54 percent of the subjects did not complete a full course of assigned treatment, primarily because of toxicity. Different problems occurred: the trimethoprim-sulfamethoxazole group had a higher incidence of hepatitis; the dapsone-trimethoprim group had more nausea and vomiting; and the clindamycin-primaquine group had more anemia than the other groups.19 These results suggest that treatment selection may be tailored to the individual patient's preexisting laboratory abnormalities or other medical problems.

Atovaquone (Mepron), an antiprotozoal agent, has good activity against P. carinii but is limited by its modest and unpredictable bioavailability. Although it is less effective than either trimethoprim-sulfamethoxazole or pentamidine, it is better tolerated.22,23

Despite effective antimicrobial therapy, mild to moderate episodes of PCP still carry a mortality risk of up to 9 percent.22 Determination of [A-a]DO2 is critical (Table 2) because the degree of impairment is the most important prognostic indicator. Almost all patients experience some deterioration in oxygenation within the first few days of therapy, probably because of the inflammatory response triggered by dying organisms.24 Although this decrease is not clinically important in mild disease, patients with poor pulmonary reserve may develop respiratory failure.

Administration of corticosteroids within the first 72 hours of anti-Pneumocystis treatment helps to prevent respiratory failure and death in AIDS patients.24 All patients with an [A-a]DO2 greater than 35 mm Hg or a PaO2 of less than 70 mm Hg should receive cortico-steroids when antimicrobial therapy is initiated.25  The standard approach is to use prednisone for 21 days (Table 6). Patients who are severely ill or unable to take oral medication may be given an equivalent dosage of intravenous methylprednisolone. The risk of reactivating tuberculosis or acquiring another infection appears to be minimal.24

TABLE 6

Adjunctive Corticosteroid Therapy in Moderate to Severe PCP

Schedule Dosage

Days 1 to 5

40 mg of prednisone twice daily

Days 6 to 10

40 mg of prednisone once daily

Days 11 to 21

20 mg of prednisone once daily*


PCP = Pneumocystis carinii pneumonia.

*—No further tapering is necessary.

TABLE 6   Adjunctive Corticosteroid Therapy in Moderate to Severe PCP

View Table

TABLE 6

Adjunctive Corticosteroid Therapy in Moderate to Severe PCP

Schedule Dosage

Days 1 to 5

40 mg of prednisone twice daily

Days 6 to 10

40 mg of prednisone once daily

Days 11 to 21

20 mg of prednisone once daily*


PCP = Pneumocystis carinii pneumonia.

*—No further tapering is necessary.

The prognosis for patients who develop respiratory failure is poor, although those who require mechanical ventilation early are more likely to recover than those who develop late respiratory failure.26 In unventilated patients, pneumothorax results in prolonged hospitalization but does not increase mortality, whereas pneumothorax in ventilator-dependent patients almost always has a fatal outcome.27 Pneumothorax may be bilateral and recurrent, necessitating long-term chest tube placement or pleurodesis.

Determining whether a patient is responding to treatment may be difficult. It is important to remember that oxygenation typically reaches a nadir approximately 72 hours after therapy is begun.24 Because it generally takes several days for clinical improvement, therapy usually should not be changed for at least five to seven days. If a patient is not responding, a bronchoscopy should be performed to rule out the presence of another opportunistic process. P. carinii will still be present but, when no change or an increase in the organism count (if available) is found, the treatment may be failing and should be modified.28

Prevention of PCP

Prophylaxis is also limited by adverse effects, and failures may occur at rates up to 33 percent, depending on the specific agent and the degree of immunosuppression defined by absolute CD4+ count.29 In addition to the factors outlined in the U.S. Public Health Service (PHS) guidelines for PCP prophylaxis,8  patients with other AIDS-defining illnesses should be considered for PCP prophylaxis (Table 1). The advent of potent combination antiretroviral therapy has led to considerably increased CD4+ cell counts in many patients whose cell counts were previously below 200 per mm3 (200 × 106 per L). Recent data indicate that such patients are indeed protected against PCP. The latest revision to the PHS guidelines will recommend discontinuation of primary PCP prophylaxis in patients whose CD4+ cell counts are sustained above 200 per mm3 for at least six months and who have well-controlled HIV viral loads.3032 Patients who do not have HIV infection but are at high risk for PCP, including those receiving aggressive therapy for leukemia or lymphoma and transplant recipients, should also receive prophylaxis.18

Trimethoprim-sulfamethoxazole is the first choice for prophylaxis (Table 7). In a meta-analysis of 35 randomized trials,33 patients regularly taking trimethoprim-sulfamethoxazole had only a 5 percent likelihood of developing PCP. Even though the dosage used for prophylaxis is much lower than that used for treatment, side effects are still common. Lower dosage regimens should be considered, because they may diminish the risk of side effects without compromising protection.8,33 If a mild reaction to trimethoprim-sulfamethoxazole develops, antihistamines often permit continued use of the agent.29,33 Desensitization has not been studied rigorously but has been useful in some cases.34 Other benefits of the trimethoprim-sulfamethoxazole regimen include protection against toxoplasmosis and bacterial infections.35

TABLE 7

Drugs for Prophylaxis of PCP

Drug Dosage Cost*

TMP-SMZ (Bactrim, Septra)

1 double-strength tablet (160 mg TMP/800 mg SMZ) orally once daily

$ 38, brand 11 to 14, generic

or

1 tablet (80 mg TMP/400 mg SMZ) orally once daily

23, brand 7 to 10, generic

or

1 double-strength tablet orally three times every week

15, brand 5 to 6, generic

Dapsone

100 mg orally once daily for PCP.

5 to 10, generic 3 to 5, generic 3, brand

In toxoplasma IgG–positive-patients: use 50-mg dapsone orally once daily, plus pyrimethamine (Daraprim), 50 mg orally every week and leucovorin, 25 mg orally every week

96 to 108, generic

or

dapsone, 200 mg orally every week, plus pyrimethamine, 75 mg orally every week, and leucovorin, 25 mg orally every week

1 to 3, generic 5, generic 96 to 108, generic

Aerosolized pentamidine (NebuPent)

300 mg aerosolized by Respirgard II jet nebulizer every month; administer in negative-airflow room to patients screened for active TB; pretreat with inhaled bronchodilator in patients who experience cough or bronchospasm

99, brand

Atovaquone (Mepron)

750 mg orally twice daily (1,500 mg per day)

833, brand


TMP = trimethoprim; SMZ = sulfamethoxazole; TB = tuberculosis.

*—Estimated cost to the pharmacist based on average wholesale prices (rounded to the nearest dollar) for one month of treatment in Red book. Montvale,N.J.: Medical Economics Data, 1999. Cost to the patient may be greater, depending on prescription filling fee.

TABLE 7   Drugs for Prophylaxis of PCP

View Table

TABLE 7

Drugs for Prophylaxis of PCP

Drug Dosage Cost*

TMP-SMZ (Bactrim, Septra)

1 double-strength tablet (160 mg TMP/800 mg SMZ) orally once daily

$ 38, brand 11 to 14, generic

or

1 tablet (80 mg TMP/400 mg SMZ) orally once daily

23, brand 7 to 10, generic

or

1 double-strength tablet orally three times every week

15, brand 5 to 6, generic

Dapsone

100 mg orally once daily for PCP.

5 to 10, generic 3 to 5, generic 3, brand

In toxoplasma IgG–positive-patients: use 50-mg dapsone orally once daily, plus pyrimethamine (Daraprim), 50 mg orally every week and leucovorin, 25 mg orally every week

96 to 108, generic

or

dapsone, 200 mg orally every week, plus pyrimethamine, 75 mg orally every week, and leucovorin, 25 mg orally every week

1 to 3, generic 5, generic 96 to 108, generic

Aerosolized pentamidine (NebuPent)

300 mg aerosolized by Respirgard II jet nebulizer every month; administer in negative-airflow room to patients screened for active TB; pretreat with inhaled bronchodilator in patients who experience cough or bronchospasm

99, brand

Atovaquone (Mepron)

750 mg orally twice daily (1,500 mg per day)

833, brand


TMP = trimethoprim; SMZ = sulfamethoxazole; TB = tuberculosis.

*—Estimated cost to the pharmacist based on average wholesale prices (rounded to the nearest dollar) for one month of treatment in Red book. Montvale,N.J.: Medical Economics Data, 1999. Cost to the patient may be greater, depending on prescription filling fee.

Dapsone is a reasonable alternative to trimethoprim-sulfamethoxazole. Dapsone in combination with weekly pyrimethamine (Daraprim) protects against PCP and toxo-plasmosis.8,36 Atovaquone is considerably more expensive than dapsone and is not yet sanctioned for this use by the Public Health Service.

Aerosolized pentamidine (NebuPent) is another option, although it is the least effective form of prophylaxis, particularly in patients with very low CD4+ cell counts.29 Although this agent is well tolerated, it is expensive and does not protect against systemic pneumocystosis, toxoplasmosis or bacterial infections. Patients should be screened for active tuberculosis before starting aerosolized pentamadine therapy to avoid the unnecessary exposure of others. Pretreatment with inhaled bronchodilators minimizes cough and bronchospasm.

Final Comment

Although advances in the care of HIV-infected patients have dramatically lowered its incidence, PCP remains a challenging clinical problem. Signs and symptoms may be insidious in onset and difficult to distinguish from those of other pathogenic processes. Patients must be monitored carefully for clinical response and drug toxicity. Family physicians need to be familiar with the presentation, diagnosis, treatment and prevention of PCP, particularly as the AIDS epidemic continues to expand beyond familiar risk groups and geographic locations.

The Authors

AIMEE WILKIN, M.D., is currently on staff at Johns Hopkins Medical Center, Baltimore. Dr. Wilkin graduated from the University of Texas Medical School at Galveston and completed a residency in internal medicine at the University of Cincinnati (Ohio) College of Medicine, where she also completed a fellowship in infectious diseases.

JUDITH FEINBERG, M.D., is professor of medicine at the University of Cincinnati College of Medicine and director of research at the Infectious Disease Center at the University of Cincinnati Medical Center, Holmes Hospital. Dr. Feinberg graduated from Rush Medical College of Rush University, Chicago, and completed a residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center, as well as a fellowship in infectious diseases at the University of California, Los Angeles, School of Medicine.

Address correspondence to Judith Feinberg, M.D., Infectious Disease Center, University of Cincinnati Medical Center, Holmes Division, Eden and Bethesda Ave., Cincinnati, OH 45267-0405. Reprints are not available from the authors.

Judith Feinberg, M.D., has received grants or research support from the National Institute of Allergy and Infectious Diseases and the following companies: Glaxo Wellcome Inc., Abbott Laboratories, Roche Pharmaceuticals and DuPont Pharma; she has served as a consultant for Glaxo Wellcome and Pharmacia & Upjohn Company; she has been a member of the speaker's bureaus of Bristol-Myers Squibb Co., Roxane Laboratories and Glaxo Wellcome.


Figure 2 provided by P.D. Walzer, M.D.

REFERENCES

1. Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30:250–2.

2. Update: acquired immunodeficiency syndrome—United States. MMWR Morb Mortal Wkly Rep. 1986;35:757–66.

3. Update: acquired immunodeficiency syndrome—United States. MMWR Morb Mortal Wkly Rep. 1986;35:17–21.

4. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus. N Engl J Med. 1998;338:853–60.

5. Cushion MT. Transmission and epidemiology. In: Walzer PD, ed. Pneumocystis carinii pneumonia. 2d ed. New York: Dekker, 1994:251–68.

6. Walzer PD. Pathogenic mechanisms. In: Walzer PD, ed. Pneumocystis carinii pneumonia. 2d ed. New York: Dekker, 1994:123–40.

7. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Eng J Med. 1990;322:161–5.

8. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infection in persons infected with human immunodeficiency virus: disease specific recommendations. Clin Infect Dis. 1997;25(suppl)3:S313–35.

9. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, et al. Pneumocystis carinii pneumonia: a comparison between patients with acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663–71.

10. Metersky ML, Colt HG, Olson LK, Shanks TG. AIDS-related spontaneous pneumothorax: risk factors and treatment. Chest. 1995;108:946–51.

11. Opravail M, Marincek B, Fuchs WA, Weber R, Speich R, Battegay M, et al. Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr. 1994;7:39–45.

12. Baughman RP. Current methods of diagnosis. In: Walzer PD, ed. Pneumocystis carinii pneumonia. 2d ed. New York: Dekker, 1994:381–401.

13. Huang L, Hecht FM, Stansell JD, Montani R, Hadley WK, Hopewell PC. Suspected Pneumocystis carinii pneumonia with a negative induced sputum examination. Is early bronchoscopy useful? Am J Respir Crit Care Med. 1995;151:1866–71.

14. Baughman RP, Dohn MN, Shipley R, Buschsbaum JA, Frame PT. Increased Pneumocystis carinii recovery from the upper lobes in pneumocystis pneumonia. Chest. 1993;103:426–32.

15. Limper AH, Offord KP, Smith TF, Martin WJ 2d. Pneumocystis carinii pneumonia: differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140:1204–9.

16. Bennett CL, Horner RD, Weinstein RA, Kessler HA, Dickinson GM, Pitrak DL, et al. Empirically treated Pneumocystis carinii pneumonia in Los Angeles, Chicago, and Miami: 1987–1990. J Infect Dis. 1995;172:312–5.

17. Baughman RP, Dohn MN, Frame PT. The continuing utility of bronchoalveolar lavage to diagnose opportunistic infections in AIDS patients. Am J Med. 1994;97:515–22.

18. Waler RE, Masur H. Current regimens of therapy and prophylaxis. In: Walzer PD, ed. Pneumocystis carinii pneumonia. 2d ed. New York: Dekker, 1994:439–66.

19. Safrin S, Finkelstein DM, Feinberg J, Frame P, Simpson G, Wu A, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med. 1996;124:792–802.

20. Sattler FR, Cowan R, Nielsen DM, Rushkin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med. 1988;109:280–7.

21. Sattler FR, Frame PT, Davis R, Nichols L, Shelton B, Akil B, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. J Infect Dis. 1994;170:165–72.

22. Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328:1521–7.

23. Dohn MN, Weinberg WG, Torres RA, Follansbee SE, Caldwell PT, Scott JD, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med. 1994;121:174–80.

24. Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1451–7.

25. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1500–4.

26. De Palo VA, Millstein BH, Mayo PH, Salzmann SH, Rosen MJ. Outcome of intensive care in patients with HIV infection. Chest. 1995;107:506–10.

27. Pastores SM, Garay SM, Naidich DP, Rom WN. Review: pneumothorax in patients with AIDS-related Pneumocystis carinii pneumonia. Am J Med Sci. 1996;312:329–34.

28. Colangelo G, Baughman RP, Dohn MN, Frame PT. Follow-up bronchoalveolar lavage in AIDS patients with Pneumocystis carinii pneumonia. Am Rev Respir Dis. 1991;143(5 pt 1):1067–71.

29. Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1995;332:693–9.

30. Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzales-Lahoz J, d'Arminio Monforte A, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet. 1999;353:1293–8.

31. Feinberg J. Withdrawal of prophylaxis against Pneumocystis carinii pneumonia [Editorial]. Lancet. 1999;353:1287.

32. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1999;48

33. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156:177–88.

34. Gluckstein D, Rushkin J. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis. 1995;20:849–53.

35. Hardy WD, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med. 1992;327:1842–8.

36. Mallolas J, Zamora L, Gatell JM, Miro JM, Vernet E, Valls M, et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS. 1993;7:59–64.


Copyright © 1999 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article